Submission & ApprovalLast reviewed April 2026

New Chemical Entity Exclusivity(NCE)

FDA's 5-year marketing exclusivity for the first approval of a drug containing a novel active moiety.

Usage Examples

The first-approval NDA received 5-year NCE exclusivity blocking ANDA and 505(b)(2) submissions for the active moiety.
Paragraph IV certification reduced effective NCE blocking period to 4 years with potential 30-month stay.

What is NCE?

New Chemical Entity (NCE) exclusivity is a 5-year period following first NDA approval during which FDA cannot accept an ANDA or 505(b)(2) application for the same active moiety. NCE exclusivity attaches to the active moiety, not the specific drug product — once a moiety has been previously approved in any form, subsequent products containing that moiety do not qualify for NCE.

The exclusivity is reduced to 4 years if a competing ANDA or 505(b)(2) applicant files a Paragraph IV certification challenging listed patents. Paragraph IV certifications during the 4-year window can trigger Hatch-Waxman patent litigation and 30-month approval stays. NCE exclusivity is independent of patent protection — a drug can have NCE without patents, or patents without NCE. Combined patent/exclusivity strategy determines effective market protection duration.

Regulatory Context

This term appears most often in submission & approval workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside FDCA SECTION 505J5F, HATCH WAXMAN ACT.

FDAICHEMA

When This Matters

The first-approval NDA received 5-year NCE exclusivity blocking ANDA and 505(b)(2) submissions for the active moiety.
Paragraph IV certification reduced effective NCE blocking period to 4 years with potential 30-month stay.

Common Mistakes

Treating submission readiness as a formatting-only check without lifecycle validation.
Using outdated guidance references across modules and summaries.
Missing cross-functional review between RA, CMC, and quality before submission.

Related Regulations

FDCA SECTION 505J5FHATCH WAXMAN ACT

Frequently Asked Questions

First FDA approval of any drug product containing a novel active moiety — meaning the moiety has not been previously approved in any form. Prodrug or ester variants of previously approved moieties typically do not qualify. The FDA Office of Generic Drugs makes the final moiety determination.

NCE (5 years) applies to first approval of a novel moiety and blocks ANDA/505(b)(2) filing. 3-year exclusivity applies to NDAs or supplements requiring new clinical investigations essential to approval and blocks ANDA/505(b)(2) approval (but not filing). They can stack for the same drug.

Only ANDAs and 505(b)(2) applications that reference the protected drug. Independent 505(b)(1) NDAs for the same indication or other active moieties are not blocked. NCE is a specific generic/hybrid barrier, not a broad market monopoly.